The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis

Joint Bone Spine

Volumn 82, Issue 2, 2015, Pages 109-115

  Briot, Karine ^a   Rouanet, Stéphanie ^b   Schaeverbeke, Thierry ^c   Etchepare, Fabien ^d   Gaudin, Philippe ^e   Perdriger, Aleth ^f   Vray, Muriel ^g   Steinberg, Ghislaine ^b   Roux, Christian ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Roche SAS   (France)

^c HÔPITAL PELLEGRIN   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e Hopital Sud CHU de Grenoble   (France)

^f SERVICE DE RHUMATOLOGIE   (France)

^g INSTITUT PASTEUR   (France)

Author keywords

Bone mineral density; Bone remodeling; DKK 1; Rheumatoid arthritis

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; DICKKOPF 1 PROTEIN; METHOTREXATE; PLACEBO; PREDNISONE; SCLEROSTIN; TOCILIZUMAB; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; COLLAGEN TYPE 1; DKK1 PROTEIN, HUMAN; GLUCOCORTICOID; INTERLEUKIN 6; MONOCLONAL ANTIBODY; SIGNAL PEPTIDE;

ADULT; ARTICLE; BONE DENSITY; BONE REMODELING; BONE TURNOVER; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; MULTICENTER STUDY;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BIOLOGICAL PRODUCTS; BONE DENSITY; BONE REMODELING; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-6; MALE; METHOTREXATE; MIDDLE AGED;

EID: 84924501727     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.10.015     Document Type: Article

References (30)

1. Roux C. Osteoporosis in inflammatory joint diseases. Osteoporos Int 2011, 22:421-433.
2. Romas E., Gillespie M.T., Martin T.J. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 2002, 30:340-346.
3. O' Gradaigh D., Ireland D., Bord S., et al. Joint erosion in rheumatoid arthritis: interactions between tumor necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. Ann Rheum Dis 2004, 63:354-359.
4. Edwards C.J., Williams E. The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis. Osteoporos Int 2010, 21:1287-1293.
5. De Benedetti F., Rucci N., Del Fattore A., et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 2006, 54:3551-3563.
6. Glinka A., Wu W., Delius H., et al. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998, 391:357-362.
7. Daoussis D., Andonopoulos A.P. The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling?. Semin Arthritis Rheum 2011, 41:170-177.
8. Diarra D., Stolina M., Polzer K., et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007, 13:156-163.
9. Wang S.Y., Liu Y.Y., Ye H., et al. Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. J Rheumatol 2011, 38:821-827.
10. Heiland G.R., Zwerina K., Baum W., et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis 2010, 69:2152-2159.
11. Ohnaka K., Taniguchi H., Kawate H., et al. Glucocorticoid enhances the expression of Dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 2004, 318:259-264.
12. Lin C., Jiang X., Dai Z., et al. Sclerostin mediates bone response to mechanical unloading via antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 2009, 24:1651-1661.
13. Karsdal M.A., Schett G., Emery P., et al. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE Study (NCT00106522). Semin Arthritis Rheum 2012, 42:131-139.
14. Hashimoto J., Garnero P., van der Heijde D., et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod Rheumatol 2011, 21:10-15.
15. Garnero P., Thompson E., Woodworth T., et al. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6-receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 2010, 62:33-43.
16. Wells G.A., Tuqwell P., Kraag G.R., et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993, 20:557-560.
17. Schaeverbeke T., Gaudin P., Perdriger A., et al. Concomitant assessment of clinical and ultrasound efficacy and safety of tocilizumab in patients with moderate to severe rheumatoid arthritis: the Torpedo Study. Arthritis Rheum 2012, 64:S204.
18. Genant H.K., Grampp S., Glüer C.C., et al. Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res 1994, 9:1503-1514.
19. Lu Y., Fuerst T., Hui S., et al. Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle. Osteoporos Int 2001, 12:438-444.
20. Chopin F., Garnero P., le Henanff A., et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67:353-357.
21. Vis M., Havaardsholm E.A., Haugeberg G., et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:1495-1499.
22. Marotte H., Pallot-Prades B., Grange L., et al. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and non-responders to infliximab. Arthritis Res Ther 2007, 9:R61.
23. Wijbrandts C.A., Klaasen R., Dijkgraaf M.G., et al. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis 2009 Mar, 68:373-376.
24. Kume K., Amano K., Yamada D., et al. The effect of tocilizumab on bone mineral density in patients with methotrexate resistant active rheumatoid arthritis. Rheumatology 2014, 53:900-903.
25. Gough A.K., Lilley J., Eyre S., et al. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994, 344:23-27.
26. Güler-Yüksel M., Bijsterbosch J., Goekoop-Ruiterman Y.P., et al. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis 2008, 67:23-28.
27. Wijbrandts C.A., Klaasen R., Dijkgraaf M.G., et al. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis 2009, 68:373-376.
28. Axmann R., Böhn C., Krönke G., et al. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum 2009, 60:2747-2756.
29. Terpos E., Fragiadaki K., Konsta M., et al. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. Clin Exp Rheumatol 2011, 29:921-925.
30. Garnero P., Tabassi N.C., Voorzanger-Rousselot N. Circulating Dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept. J Rheumatol 2008, 35:2313-2315.